Capstan's lead asset, CPTX2309, is a targeted lipid nanoparticle (tLNP) that delivers an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR) to CD8-expressing cytotoxic T cells in vivo
If approved, linerixibat could address high unmet medical need of patients living with cholestatic pruritus (relentless itch) and related sleep interference
his is the second license extension of a Nurix autoimmune disease program by Sanofi in the last 90 days
Enpatoran is a potential first-in-class oral therapy for CLE and SLE that is thought to selectively block the activation of Toll-like receptors (TLR)7 and TLR8
Express Scripts has added YESINTEK to the National Preferred Formulary (NPF) effective March 21, 2025
The study demonstrated equivalent efficacy, safety, immunogenicity, and pharmacokinetics between YESINTEK and the reference product Stelara
YESINTEK is approved for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis
Itolizumab achieved key secondary endpoint of endoscopic remission of 16.7% compared to 16.7% for adalimumab and 6.7% for placebo
This product is an oral SYK inhibitor and suppresses platelet destruction by macrophages and platelet depletion
DOVBLERON marks the 13th addition to Innovent’s commercial portfolio
Subscribe To Our Newsletter & Stay Updated
